



NEWS RELEASE

IZOTROPIC UNAWARE OF ANY MATERIAL CHANGE

FOR IMMEDIATE RELEASE

October 26, 2020

At the request of IIROC, Izotropic Corporation ("Izotropic Corporation" or the "Company") wishes to confirm that the Company's management is unaware of any material change in the Company's operations that would account for the recent increase in market activity.

"Izotropic Corporation" is engaged in the commercialization of proprietary diagnostic products for breast cancer. Its business strategy is to complete the commercial development of 360 degree, true 3D breast imaging technology for early diagnosis of breast cancer. The Company holds a license under a license agreement to make, have made, use, offer for sale, import, and sell products and services and to practice processes and methods in the field of human diagnostics and therapeutics in the United States and any other countries where approvals are granted or where patent rights may exist in the future with respect to certain licensed patent rights.

This news release may contain assumptions, estimates, and other forward-looking statements regarding future events. Such forward-looking statements involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control that may cause actual results or performance to differ materially from those currently anticipated in such statements.

FOR FURTHER INFORMATION PLEASE CONTACT:

Robert Thast
Chief Executive Officer

Phone: 1-833-IZOCORP
Email: info@izocorp.com
Website: izocorp.com

ON BEHALF OF THE BOARD

1-833-IZOCORP
izocorp.com
info@izocorp.com

Suite 424, 800-15355 24th Avenue
Surrey BC Canada, V4A 2H9

Robert Thast
Chief Executive Officer

About Izotropic Corp.

Izotropic Corporation and its wholly owned U.S. operating subsidiary, Izotropic Imaging Corp. have been established to commercialize the next generation of breast imaging technology for early diagnosis of breast cancer. The Izotropic Breast CT Imaging System produces high resolution breast images in 3D. A single 10 second breast CT scan acquires approximately 500 images, without painful breast compression, providing radiologists with fully 3D viewing of the scanned breast.

Mammography scanning requires compression of the breast between 2 imaging plates, resulting in 2D images.

The Company has the exclusive worldwide license from the University of California, Davis (UC Davis) to commercialize the technology developed by principal founder and Company director Dr. John M. Boone and researchers at UC Davis. The license includes all intellectual property, trade secrets, patents and patent-pending applications that are the foundation of the Company's breast CT imaging platform.

Approximately \$20 million in research funding and over 15 years of research and development have been invested in developing this groundbreaking breast CT imaging technology. Research includes a current, ongoing \$2.9M U.S. clinical trial at UC Davis Medical Center.

The Company founders believe that this technology will be a disruptive entry to the market, overcoming many of the challenges faced by existing breast imaging modalities.